Related Experiment Video

Updated: Oct 18, 2025

Implantation of Total Artificial Heart in Congenital Heart Disease
07:27

Implantation of Total Artificial Heart in Congenital Heart Disease

Published on: July 18, 2014

24.8K

Overweight and Obesity in Patients with Congenital Heart Disease: A Systematic Review

Laura Willinger1, Leon Brudy1, Michael Meyer1

  • 1Department of Congenital Heart Disease and Pediatric Cardiology, Deutsches Herzzentrum München, Technische Universität München, 80636 Munich, Germany.

International Journal of Environmental Research and Public Health
|September 28, 2021
PubMed

Insights

Overweight and obesity prevalence in children and adults with congenital heart disease (CHD) mirrors the general population. This growing pandemic also impacts individuals with CHD, highlighting a significant public health concern.

Area of Science:

  • Cardiology
  • Public Health
  • Pediatrics

Background:

  • Overweight and obesity are significant public health issues.
  • Congenital heart disease (CHD) patients face increased health risks.
  • Understanding weight trends in CHD is crucial for management.

Purpose of the Study:

  • To systematically review the prevalence of overweight and obesity in children and adults with CHD.
  • To examine the longitudinal development of overweight and obesity in this population.

Main Methods:

  • A systematic literature search was performed across PubMed, Cochrane, and Scopus.
  • Studies published between January 2010 and December 2020 were included.
  • Data from 30 studies involving over 22,000 patients were analyzed.

Main Results:

  • Overweight prevalence in children with CHD ranged from 9.5-31.5%; obesity from 9.5-26%.
  • In adults with CHD (ACHD), overweight prevalence was 22-53%; obesity was 7-26%.
  • Prevalence rates were comparable to the general population and increased with age.

Conclusions:

  • Overweight and obesity are prevalent in both pediatric and adult CHD populations.
  • These weight issues are as common in CHD patients as in the general population.
  • The global obesity pandemic affects individuals with CHD, necessitating focused attention.
Abstract

Keywords:
body constitutioncongenital heart diseaseobesityoverweight

More Related Videos

Fetal Mouse Cardiovascular Imaging Using a High-frequency Ultrasound 30/45MHZ System07:34

Fetal Mouse Cardiovascular Imaging Using a High-frequency Ultrasound 30/45MHZ System

Published on: May 5, 2018

11.8K
Multidisciplinary Approach to Obesity Management: A Case Report05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

491

Related Concept Videos

Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
22
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
24
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
27
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
57
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
104
Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
719